Question 1: What is the indication for CIBMTR Research ID (CRID) assignment?
Indicate whether the individual will be receiving hematopoietic cellular transplant (HCT), non-transplant cellular therapy, marrow toxic injury therapy, or non-cellular therapy.
Hematopoietic cellular transplant (HCT) is a transplant of bone marrow, peripheral blood stem cells, umbilical cord blood, or other cellular product containing CD34+ cells, also known as hematopoietic progenitor cells. If the infusion type is gene therapy, select “Hematopoietic cellular transplant.”
Non-transplant cellular therapies may be derived from a hematopoietic or non-hematopoietic tissue source and can be utilized for a broad range of indications, including autoimmune, cardiovascular, peripheral vascular, and neurologic diseases; these are often referred to as cellular therapies for regenerative medicine (CTRM).
Marrow toxic injury should only be reported by Radiation Injury Treatment Network (RITN) centers in the event of mass casualty incident resulting in marrow toxic injury. Do not report marrow toxic injury for individuals receiving pre-transplant radiation therapy or for accidental, isolated exposures to radiation.
If you are completing this form for a patient at a RITN center and are uncertain if the patient’s data should be reported using the marrow toxic injury indication, contact your CIBMTR CRC or email RITN@nmdp.org.
Non-cellular therapy may include vaccine or immunomodulatory trials; report non-cellular therapy when the patient is enrolled on a trial or protocol requiring data submission to CIBMTR.
If the reported indication is:
- Hematopoietic cellular transplant, complete questions 2-5.
- Non-transplant cellular therapy, complete question 6
- Marrow toxic injury, complete question 7
- Non-cellular therapy, complete questions 8-10.
|Question Number||Date of Change||Add/Remove/Modify||Description||Reasoning (If applicable)|